Valiant OrganicsQ3 FY23

Valiant Organics Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹348.2P/E: 17.5Market Cap: ₹976 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 4
  • PAP (Paracetamol raw material) production expected to ramp up from 400+ MT/month to around 800-900 MT/month, contributing 20-30% to total revenue in next 2-3 years.
  • FY '24 revenue guidance is flattish at around Rs. 900-950 crores due to subdued demand in dyes intermediates and ongoing ramp-up of Sarigam plant.
  • 20-25% growth anticipated in FY '24 driven by PAP ramp-up and pharma intermediates project becoming operational.
  • Focus on stabilizing and optimizing capacity utilization (80-85%) in existing and new plants like PAP and pharma intermediates over next 1-2 years.
  • Medium to long-term outlook positive with expected industry tailwinds (China plus 1 strategy, Indian specialty chemical sector growth).
  • Emphasis on expanding production capacity cautiously with efforts to improve asset turnover and margins around 18-22% EBITDA.
  • Pilot pharma intermediates plant expected to scale up commercially in about a year with utilization at 70-80%.

See what Valiant Organics management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • Currently, Valiant Organics has term loans amounting to ₹113 crores and is not looking to take any further loans in the near future.
  • The company aims to continue repaying and reducing its debt as per the existing repayment schedule until FY '26.
  • Debt-free status is unlikely soon, as future big CAPEX may require additional term loans.
  • Cash flows are expected to improve once PAP ramp-up generates adequate accruals.
  • Regarding equity fundraising, specifically the IPO of Valiant Laboratories (formerly Bharat Chemicals), the management has not disclosed detailed information as discussions are ongoing and sensitive due to competitive reasons.
  • No explicit timelines or plans for the IPO or other equity fundraising were shared during the call.

See what Valiant Organics management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Pharma Intermediates project: CAPEX of around ₹80-85 crores has been committed; currently at pilot stage with scope to expand (Page 15).
  • PAP plant: Additional CAPEX planned to convert batch process into semi-continuous; CAPEX not significant (Page 17).
  • No major new CAPEX planned in near future; future large CAPEX possible 2-3 years down the line (Page 13, 6).
  • Current debt repayment plan ongoing until FY '26; future CAPEX may lead to additional term loans (Page 6).
  • Focus on ramping up existing projects like PAP and Pharma Intermediates rather than fresh large investments immediately (Page 6, 12).
  • Discussions ongoing on new product development and chlorination expansion, likely 2 years out (Page 13).

Track Valiant Organics — get its next earnings analysis in your feed

How does Valiant Organics rank vs peers in Chemicals & Petrochemicals?

Pro feature
ThisValiant Organics
Rev 4Mar 3

How does Valiant Organics rank in Chemicals & Petrochemicals?

Compare Valiant Organics against every Chemicals & Petrochemicals company (Q3 FY23) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

Others in Chemicals & Petrochemicals this season

  • Seya Industries (Q2 FY27)

    Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's

  • DCM Shriram Fine Chemicals (Q2 FY27)

    9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri

  • Dhariwalcorp (Q2 FY27)

    For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…

  • Agastya Energy (Q2 FY27)

    For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →